There aren't many hotter stocks on the market right now than Viking Therapeutics (NASDAQ: VKTX). Shares of the biopharmaceutical company have skyrocketed around 340% so far this year.

However, those impressive gains might be just a start for Viking. The company should have plenty of potential catalysts over the next few years. Could Viking Therapeutics stock be a millionaire-maker?

Investors' excitement about Viking Therapeutics reached a fever pitch on Feb. 27, 2024, when the company announced the results from a phase 2 clinical study evaluating VK2735 in patients with obesity. Viking reported its experimental drug helped patients achieve a placebo-adjusted mean weight loss of up to 13.1% after 13 weeks of treatment. This reflected faster weight loss than Novo Nordisk's Wegovy and Ei Lilly's Zepbound achieved in their clinical trials.

Continue reading

Source Fool.com